...
首页> 外文期刊>The American Journal of the Medical Sciences >Limb-Girdle Muscular Dystrophy 2B and Miyoshi Presentations of Dysferlinopathy
【24h】

Limb-Girdle Muscular Dystrophy 2B and Miyoshi Presentations of Dysferlinopathy

机译:肢体肌肉营养不良2b和miyoshi介绍的痢疾疾病

获取原文
获取原文并翻译 | 示例

摘要

Abstract We report the following 2 subtypes of progressive limb-girdle dystrophy type 2B: limb-girdle muscular dystrophy type 2B (LGMD2B) and Miyoshi. The first patient described had weakness in the anterior thigh muscles (LGMD2B) and the second patient had calf muscle weakness and atrophy (Miyoshi). Literature review was performed and LGMD2B was compared and distinguished from other myopathies of similar nature. Genetic testing with polymerase chain reaction analysis of the DYSF gene confirmed the diagnosis in both patients. Additional findings of histopathology, specific stain for sarcolemmal membrane protein, Western blot analysis and clinical presentation clinched the diagnosis further of dysferlinopathy (LGMD2B) in both our patients. Currently, there is no definitive treatment on the horizon and immunosuppressive therapy is not recommended for this condition. Gene therapy may have a future role, but at present, muscle-strengthening exercises and patient awareness are the mainstays.
机译:摘要我们报告了以下2型渐进式肢体营养不良型2B:肢体肌营养不良型2B(LGMD2B)和Miyoshi的亚型。描述的第一个患者在前大腿肌肉(LGMD2B)中具有弱点,第二患者具有小腿肌肉无力和萎缩(Miyoshi)。进行了文献综述,并将LGMD2B进行了比较,与其他类似性质的其他肌病区分开来。具有Dysf基因的聚合酶链反应分析的遗传检测证实了两种患者的诊断。 Sarcolemmal膜蛋白,Western印迹分析和临床介绍的特异性染色的其他结果均在两种患者中进一步诊断痢疾(LGMD2B)的诊断。目前,不建议在这种情况下对地平线和免疫抑制治疗治疗。基因疗法可能具有未来的作用,但目前,肌肉加强练习和患者意识是主体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号